



**Patient Group Direction for the Administration of Hepatitis B Vaccine  
 for Non-Travel Indications by Approved Healthcare Professionals  
 Working Within NHS Grampian, Highland, Orkney, Shetland, Tayside  
 and Western Isles**

<b>Lead Author:</b> Adapted from Public Health Scotland Administration of Hepatitis B Vaccine for Non-Travel Indications Patient Group Direction (PGD) Template Version 2.1 – PHS Publication date July 2022		<b>Approver:</b> NoS PGD Group  <b>Authorisation:</b> NHS Grampian
--	--	--

<b>Signature:</b> 		<b>Signature:</b> 
--	--	--

<b>NoS Identifier:</b> NoS/PGD/HepB/1472	<b>Review Date:</b> 28 <sup>th</sup> February 2026  <b>Expiry Date:</b> 28 <sup>th</sup> February 2026	<b>Date Approved by NoS:</b> 20 <sup>th</sup> November 2024 (Amended November 2024)
---	--	---

NHS Grampian, Highland, Orkney, Shetland, Tayside and Western Isles have  
 authorised this Patient Group Direction to help individuals by providing them with  
 more convenient access to an efficient and clearly defined service within the NHS  
 Boards. This Patient Group Direction cannot be used until Appendix 1 and 2 are  
 completed.

**Uncontrolled when printed**  
  
**Version 2.1.1 (Amended November 2024)**

**Revision History for NoS:**

<b>NoS PGD that has been superseded</b>	NoS/PGD/HepB/1472, Version 2.1 (previous version number NoS_1306)
---	--

**Most recent changes NoS**

Version	Date of change	Summary of Changes	Section heading
2.0	01 February 2024 (PHS Version Unpublished by NoS)	As per PHS version history see section 7	
2.1	08 August 2024	Reference to NoS Appendix 1 and 2	Authorisation
		Training requirements for NoS	Continuing education and training
2.1.1	November 2024	Administrative error – Superseded version number incorrect. See above.	Revision History for NoS

**PHS recent changes**

Version	Date	Summary of changes
2.1	22 July 2024	<p>The following changes to version 2.0 of the PGD have been made:</p> <ul style="list-style-type: none"> <li>Section 1.2 inclusions updated with new inclusion for those with uncertain or incomplete immunisation status and displaced persons (e.g. asylum seekers, trafficked people and refugees) who are living in multiple occupancy rooms or share bathroom facilities such as a hostel, hotel or looked after children's unit.</li> <li>Exclusion criteria to reflect Green Book wording on previous infection.</li> <li>Section 2.1 name of product updated with additional brands.</li> <li>Dosage and Frequency sections updated to reference relevant tables in Chapter 18</li> <li>Section 2.8 updated with additional brands.</li> <li>Section 2.10 updated with additional brands.</li> <li>Section 3.1 updated to align with Green Book chapter wording.</li> </ul>

**Review date:** The review date for a PGD needs to be decided on a case-by-case basis in the interest of safety. The expiry date should not be more than 3 years, unless a change in national policy or update is required.

<b>Contents Page</b>	<b>Page No.</b>
Authorisation	3
1. Clinical situation	4
2. Description of treatment	7
3. Adverse reactions	11
4. Characteristics of staff authorised under the PGD	13
5. Audit trail	14
6. Additional references	15
7. PHS Version history	15
Appendix 1 - Healthcare Professional Agreement to Administer Medicine(s) Under Patient Group Direction	17
Appendix 2 - Healthcare Professionals Authorisation to Administer Medicine(s) Under Patient Group Direction	18

## Authorisation




This specimen Patient Group Direction (PGD) template has been produced by Public Health Scotland and adapted by North of Scotland PGD Group (NoS) to assist NHS Boards. NHS Boards should ensure that the final PGD is considered and approved in line with local clinical governance arrangements for PGDs.

The qualified health professionals who may administer vaccine under this PGD can only do so as named individuals. It is the responsibility of each professional to practice within the bounds of their own competence and in accordance with their own Code of Professional Conduct and to ensure familiarity with the manufacturer's product information/Summary of Product Characteristics (SmPC) for all vaccines administered in accordance with this PGD.

NHS Board governance arrangements will indicate how records of staff authorised to operate this PGD will be maintained. Under PGD legislation there can be no delegation. Administration of the vaccine has to be by the same practitioner who has assessed the patient under the PGD.

All authorised staff are required to read the PGD and sign the Agreement to Administer Medicines Under PGD ([Appendix 1](#)).


A Certificate of Authorisation ([Appendix 2](#)) signed by the authorising professional/manager should be supplied. This should be held in the individual health professional's records, or as agreed within the individual Health Board.

This PGD has been produced for NoS by:					
Doctor	Danny Chandler	Signature		Date Signed	10/10/2024
Pharmacist	Fiona Marion	Signature		Date Signed	22/10/2024
Nurse	Pauline Merchant	Signature		Date Signed	04/10/2024

### Approved for use within NoS by:

NoS Group Chair	Signature	Date Signed
Lesley Coyle		05/12/2024

### Authorised and executively signed for use within NoS by:

NHS Grampian Chief Executive	Signature	Date Signed
Adam Coldwells – Interim Chief Executive		20/11/2024

### Version 2.1.1 – Approved for NoS from 5<sup>th</sup> December 2024

# 1. Clinical situation

## 1.1. Indication

Active immunisation of individuals who are deemed to be at risk from exposure to hepatitis B virus.

## 1.2. Inclusion criteria

### Post-exposure

Individuals who:

- are babies born to hepatitis B infected mothers
- have been potentially exposed to hepatitis B infected blood or body fluids

### Pre-exposure

Individuals who:

- have chronic liver disease (for instance those who have severe liver disease, such as cirrhosis of any cause, or have milder liver disease and may share risk factors for acquiring hepatitis B infection, such as individuals with chronic hepatitis C)
- have haemophilia or receive regular blood products and carers responsible for administration of these products
- are people who inject drugs (PWID) or those who are likely to progress to be injecting drugs, their sexual partners, children, other household and close family contacts of this group
- change sexual partners frequently, are men who have sex with men (GBMSM) or commercial sex workers
- Individuals with uncertain or incomplete immunisation status in accordance with the [vaccination of individuals with uncertain or incomplete immunisation status](#) flow chart.
- are rough sleepers or live in hostel accommodation
- displaced persons (e.g. asylum seekers, trafficked people and refugees) who are living in multiple occupancy rooms or share bathroom facilities such as a hostel, hotel or looked after children's unit are household, close family or sexual contacts of an individual with hepatitis B infection
- are members of a family adopting children from countries with a high or intermediate prevalence of hepatitis B
- are, or are close family or household of, short-term foster carers who receive emergency placements
- are, or are close family or household of, permanent foster carers who accept a child known to be hepatitis B infected
- are inmates of custodial institutions in the UK, including those on remand
- are resident in accommodation for those with learning disabilities

- are adults or children attending day care, schools and centres for those with learning disabilities and, based on local risk assessment, are at risk of percutaneous exposure (such as biting or being bitten) on a regular basis
- are individuals who are 15 years of age or over and are on haemodialysis, a renal transplantation programme or have chronic renal failure (CKD stage 4 or 5) that is likely to require haemodialysis or transplant
- are healthcare workers (including students and trainees) at occupational risk,
- are laboratory workers who have direct contact with patient's blood or blood-stained body fluids or patient's tissues working directly with the virus,
- are staff of residential and other accommodation for those with learning difficulties
- are staff of custodial institutions

Valid consent has been given to receive the vaccine.

### 1.3. Exclusion criteria

Individuals who:

- have had a confirmed anaphylactic reaction to a previous dose of any hepatitis B containing vaccine or to any components of the vaccines (refer to relevant SmPC)
- are known to be HBsAg, anti-HBs or anti-HBc positive
- have a history of severe (i.e. anaphylactic reaction) to latex where the vaccine is not latex free
- are suffering from acute severe febrile illness (the presence of a minor infection is not a contraindication for immunisation)
- are aged under 15 years when the vaccine is for haemodialysis, a renal transplantation programme or have chronic renal failure (CKD stage 4 or 5) that is likely to require haemodialysis or transplant

### 1.4. Cautions/need for further advice/circumstances when further advice should be sought from a doctor

The Green Book advises there are very few individuals who cannot receive hepatitis B-containing vaccines.

When there is doubt, appropriate advice should be sought from the immunisation co-ordinator or health protection team rather than withholding the vaccine.

The presence of a neurological condition is not a contraindication to immunisation but if there is evidence of current neurological deterioration, deferral of vaccination may be considered, to avoid incorrect attribution of any change in the underlying condition. The risk of such deferral should be balanced against the risk of the preventable infection, and vaccination should be promptly given once the diagnosis and/or the expected course of the condition becomes clear.

## Co-administration of other vaccines

Hepatitis B vaccines can be given at the same time as other vaccines, including other travel vaccines. When administering at the same time as other vaccines, care should be taken to ensure that the appropriate route of injection is used for all the vaccinations. The vaccines should be given at separate sites, preferably in different limbs. If given in the same limb, they should be given at least 2.5cm apart. The site at which each was given should be noted in the individual's records.

## Syncope

Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints.

## Pregnancy and breastfeeding

There is no evidence of risk from vaccinating pregnant women or those who are breast feeding with inactivated vaccines. Since hepatitis B vaccine is an inactivated vaccine, the risks to the foetus are negligible and it should be given where there is a definite risk of infection.

## 1.5 Action if excluded

Specialist advice must be sought on the vaccine and circumstances under which it could be given. Immunisation using a patient specific direction may be indicated.

The risk to the individual of not being immunised must be taken into account.

Document the reason for exclusion and any action taken in accordance with local procedures.

Inform or refer to the clinician in charge.

Advise individuals of preventative measures to reduce exposure to hepatitis B (such as avoiding exposure to blood and bodily fluids).

Individuals who are under 15 years of age who are on haemodialysis, renal transplantation programmes or with chronic renal failure (CKD stage 4 or 5) that is likely to require haemodialysis or transplant, should be referred for specialist advice on the appropriate vaccination schedule. A PSD is required as vaccination of these individuals is outside the remit of this PGD.

Individuals known to be HBsAg, anti-HBs or anti-HBc positive do not require further immunisation. However, immunisation should not be delayed while awaiting any test results.

## Temporary exclusion

In case of postponement due to acute severe febrile illness, arrange a future date for immunisation.

### 1.6. Action if patient declines

Advise the individual about the protective effects of the vaccine, the risks of infection and potential complications of disease.

Advise how future immunisation may be accessed if they subsequently decide to receive the vaccine.

Advise individuals of preventative measures to reduce exposure to hepatitis B (such as avoiding exposure to blood and bodily fluids).

Document advice given and decision reached.

Inform or refer to the clinician in charge.

## 2. Description of treatment

### 2.1. Name of medicine/form/strength

Hepatitis B recombinant DNA (rDNA) vaccine (adsorbed) (HepB)

- **Engerix B**<sup>®</sup> 10micrograms/0.5ml suspension for injection in prefilled syringe
- **Engerix B**<sup>®</sup> 20micrograms/1ml suspension for injection in prefilled syringe
- **HBvaxPRO Paediatric**<sup>®</sup> 5micrograms/0.5ml suspension for injection in prefilled syringe
- **HBvaxPRO**<sup>®</sup> 10micrograms/1ml suspension for injection in prefilled syringe
- **Fendrix**<sup>®</sup> 20 micrograms/0.5ml suspension for injection in pre-filled syringe
- **HBvaxPRO**<sup>®</sup> 40micrograms/1ml suspension for injection in a vial
- **PreHevbri**<sup>®</sup> 10 micrograms/1ml suspension for injection in a vial
- **HEPLISAV B**<sup>®</sup> 20 micrograms/ 0.5ml solution for injection in a pre-filled syringe

### 2.2. Route of administration

Hepatitis B-containing vaccines are routinely given intramuscularly in the upper arm or anterolateral thigh. For individuals with a bleeding disorder, vaccines normally given by an intramuscular route should be given in accordance with the recommendations in the Green Book Chapter 4.

The vaccine should be visually inspected for particulate matter and discoloration prior to administration.



In the event of any foreign particulate matter and/or variation of physical aspect being observed, do not administer the vaccine.

## 2.3. Dosage

Dependent on product, see Table 18.2 Dosage of monovalent hepatitis B containing vaccines by age in [Chapter 18](#).

## 2.4. Frequency

### Pre- and post-exposure prophylaxis schedules

Refer to Table 18.5: Hepatitis B immunisation schedules in [Chapter 18](#) and relevant indication sections for the recommended schedule(s).

It is important immunisations are provided on time, as delay will increase the chance of infection being acquired.

Where immunisation has been delayed beyond the recommended intervals, the vaccine course should be resumed and completed.

Post-exposure prophylaxis should be initiated rapidly.

Babies born to hepatitis B infected mothers should receive the first dose of vaccine as soon as possible, ideally within 24 hours of birth.

Individuals who require other vaccines at the same time as a scheduled HepB dose may receive these as separate vaccine products or the scheduled HepB dose may be fulfilled by the administration of a multivalent vaccine, such as HepA/HepB combined vaccine or DTaP/IPV/Hib/HepB (see the HepA/B vaccine PGD or DTAP/IPV/Hib/HepB PGD as appropriate).

Note: Scheduled hepatitis B vaccine doses may be fulfilled by multivalent vaccine when appropriate. This PGD does not cover the administration of multivalent vaccines.

Testing for evidence of immunity post immunisation (anti-HBs) is not routinely recommended, except for those groups set out in The 'Green Book' [Chapter 18](#). **Any additional doses required should be provided via PSD.**

### Schedule for adolescents and adults with renal insufficiency including dialysis

Refer to [Table 18.5: Hepatitis B immunisation schedules](#) in Chapter 18 and relevant indication sections for the recommended schedule(s).

Where immunisation has been delayed beyond the recommended intervals, the vaccine course should be resumed but not repeated.

HBvaxPRO<sup>®</sup> and Engerix B<sup>®</sup> may be used interchangeably to complete the vaccine course. Once the primary immunisation schedule has been started with Fendrix<sup>®</sup>, interchanging with other brands of hepatitis B vaccine is off label.

## 2.5. Duration of treatment

See frequency section.

## 2.6. Maximum or minimum treatment period

See frequency section.

## 2.7. Quantity to supply/administer

See frequency section.

## 2.8. ▼ black triangle medicines

Yes, PreHevbri<sup>®</sup> and HEPLISAV B<sup>®</sup>. The Medicines and Healthcare products Regulatory Agency (MHRA) has a specific interest in the reporting of adverse drug reactions for newly approved vaccines. All suspected adverse drug reactions should be reported using the MHRA Yellow Card Scheme.

## 2.9. Legal category

Prescription only medicine (POM).

## 2.10. Is the use outwith the SmPC?

As there is little or no data pertaining to use of either PreHevbri<sup>®</sup> or HEPLISAV B<sup>®</sup> in the paediatric population, neither of these vaccines should be given to individuals under 18 years. Whilst it is preferable that the same vaccine brand is used throughout the course, PreHevbri<sup>®</sup> or HEPLISAV B<sup>®</sup> may be given if the brand used for the first dose is not available, to avoid a delay in protection.

Engerix B<sup>®</sup> very rapid schedule (given at 0, 7 and 21 days) is licensed for those from 18 years of age but may be used off-label in those from 16 to 18 years of age where it is important to provide rapid protection and to maximise compliance (this includes PWID and those in prison) in accordance with [Chapter 18](#) of the Green Book.

Administration of Fendrix<sup>®</sup> by deep subcutaneous injection to patients with a bleeding disorder is off-label administration in line with advice in [Chapter 4](#) and [Chapter 18](#) of the Green Book.

Once the primary immunisation schedule has been started with Fendrix<sup>®</sup>, interchanging with other brands of hepatitis B vaccine is off label.

Recommendations in the Green Book [Chapter 18](#) allow for concomitant administration of hepatitis B vaccine with other vaccines at a separate site when required. For Fendrix<sup>®</sup>, such administration would be off-label as, due to a lack of data, the SmPC for Fendrix<sup>®</sup> advises an interval of 2 to 3 weeks be respected between the administration of Fendrix<sup>®</sup> and other vaccines.

Where a vaccine is recommended off-label consider, as part of the consent process, informing the individual/parent/carer that the vaccine is being offered in accordance with national guidance but that this is outside the product licence. Vaccine should be stored according to the conditions detailed below.

However, in the event of an inadvertent or unavoidable deviation of these conditions refer to NHS Board guidance on storage and handling of vaccines or national vaccine incident guidance.

Where vaccine is assessed in accordance with these guidelines as appropriate for continued use, administration under this PGD is allowed.

## 2.11. Storage requirements

Vaccine should be stored at a temperature of +2° to +8°C.

Store in the original packaging to protect from light.

Do not freeze.

NHS Board guidance on Storage and Handling of vaccines should be observed.

In the event of an inadvertent or unavoidable deviation of these conditions, vaccine that has been stored outside the conditions stated above should be quarantined and risk assessed for suitability of continued off-label use or appropriate disposal.

## 2.12. Additional information

Minor illnesses without fever or systemic upset are not valid reasons to postpone immunisation. If an individual is acutely unwell, immunisation may be postponed until they have fully recovered.

Premature infants should have their immunisations at the appropriate chronological age, according to the schedule. This is vital for infants born to hepatitis B infected mothers, as delay will increase the chance of infection being acquired. However, the occurrence of apnoea following vaccination is especially increased in infants who were born very prematurely. Therefore, very premature infants (born ≤ 28 weeks of gestation) who are in hospital should have respiratory monitoring for 48-72 hours when given their first immunisation, particularly those with a previous history of respiratory immaturity. If the infant has apnoea, bradycardia or desaturations after the first immunisation, the second immunisation should also be given in hospital, with respiratory monitoring for 48-72 hours. As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.

Immunological response may be diminished in those receiving immunosuppressive treatment.

Sexual contacts of individuals infected with hepatitis B should be advised regarding the appropriate use of condoms; a reasonable level of protection can be assumed following the second dose, provided completion of the schedule can be assured. Hepatitis B vaccine may be given to HIV-infected individuals and should be offered to those at risk, since infection acquired by immunosuppressed, HIV- positive patients can result in higher rates of chronic infection. Response rates are usually lower depending upon the degree of immunosuppression. Increasing the number of doses or using a higher antigen content dose may improve the anti-HBs response in HIV-infected individuals. Further guidance is provided by the Royal College of Paediatrics and Child Health ([www.rcpch.ac.uk](http://www.rcpch.ac.uk)) the British HIV Association (BHIVA) immunisation guidelines for HIV-infected adults (BHIVA, 2015) and the Children's HIV Association (CHIVA) immunisation guidelines (<http://www.chiva.org.uk/guidelines/immunisation/>). There should be no delay in offering vaccination to individuals in whom HIV status is not known.

Because of the long incubation period of hepatitis B, it is possible for unrecognised infection to be present at the time of immunisation. The vaccine may not prevent hepatitis B infection in such cases.

The vaccine will not prevent infection caused by other pathogens known to infect the liver such as hepatitis A, hepatitis C and hepatitis E viruses.

### **3. Adverse reactions**

#### **3.1. Warnings including possible adverse reactions and management of these**

For full details/information on possible side effects, refer to the marketing authorisation holder's SmPC.

Hepatitis B vaccine is generally well tolerated and the most common adverse reactions are soreness and redness at the injection site. Other reactions that have been reported but may not be causally related include fever, rash, malaise and an influenza-like syndrome, arthritis, arthralgia, myalgia and abnormal liver function tests. Headache is a very common reaction to both PreHevbri<sup>®</sup> and HEPLISAV B<sup>®</sup> vaccine.

As with all vaccines there is a very small possibility of anaphylaxis and facilities for its management must be available.

In the event of severe adverse reaction individual should be advised to seek medical advice.

## 3.2. Reporting procedure for adverse reactions

Healthcare professionals and individuals/carers should report all suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) using the Yellow Card reporting scheme on <http://www.mhra.gov.uk/yellowcard>

Any adverse reaction to a vaccine should be documented in accordance with locally agreed procedures in the individual's record and the individual's GP should be informed.

## 3.3. Advice to patient or carer including written information

Written information to be given to individuals:

- Provide manufacturer's consumer information leaflet/patient information leaflet (PIL) provided with the vaccine.
- Supply immunisation promotional material as appropriate.

Individual advice / follow up treatment:

- Inform the individual/carer of possible side effects and their management
- The individual should be advised to seek medical advice in the event of a severe adverse reaction.
- Inform the individual that they can report suspected adverse reactions to the MHRA using the [Yellow Card reporting scheme](#).
- When applicable, advise individual/parent/carer when the subsequent dose is due.
- Advise individuals of preventative measures to reduce exposure to hepatitis B (such as avoiding exposure to blood and bodily fluids).

Individuals/carers should be informed about the importance of completing a course of hepatitis B immunisation. Hepatitis B infected mothers whose babies are on the neonatal hepatitis B immunisation pathway should be informed of the importance of completing the course on time and for baby to be tested at age 12 months to identify if they have become chronically infected with hepatitis B.

## 3.4. Observation following vaccination

Following immunisation, patients remain under observation in line with NHS Board policy.

As syncope (fainting) can occur following vaccination, all vaccinees should either be driven by someone else or should not drive for 15 minutes after vaccination.

## 3.5. Follow up

As above.

## 3.6. Additional facilities

A protocol for the management of anaphylaxis and an anaphylaxis pack must always be available whenever vaccines are given. Immediate treatment should include early treatment with intramuscular adrenaline, with an early call for help and further IM adrenaline every 5 minutes.

The health professionals overseeing the immunisation service must be trained to recognise an anaphylactic reaction and be familiar with techniques for resuscitation of a patient with anaphylaxis.

## 4. Characteristics of staff authorised under the PGD

### 4.1. Professional qualifications

The following classes of registered healthcare practitioners are permitted to administer this vaccine:

- nurses and midwives currently registered with the Nursing and Midwifery Council (NMC)
- pharmacists currently registered with the General Pharmaceutical Council (GPhC)
- pharmacy technicians currently registered with the General Pharmaceutical Council (GPhC)
- chiropodists/podiatrists, dieticians, occupational therapists, orthoptists, orthotists/prosthetists, paramedics, physiotherapists, radiographers and speech and language therapists currently registered with the Health and Care Professions Council (HCPC)
- dental hygienists and dental therapists registered with the General Dental Council
- optometrists registered with the General Optical Council.

### 4.2. Specialist competencies or qualifications

Persons must only work under this PGD where they are competent to do so.

#### **All persons operating this PGD:**

- demonstrate appropriate knowledge and skills to work under this PGD.
- must be authorised by name by their employer as an approved person under the current terms of this PGD before working to it.
- must be familiar with the vaccine product and alert to changes in the manufacturer's product information/SmPC.
- must be competent to undertake immunisation and to discuss issues related to immunisation to assess patients for vaccination and obtain consent.

- must be competent in the correct storage of vaccines and management of the cold chain if receiving, responsible for, or handling the vaccine.
- must be competent in the recognition and management of anaphylaxis or under the supervision of persons able to respond appropriately to immediate adverse reactions.
- must have access to the PGD and associated online resources.
- should fulfil any additional requirements defined by local policy.

## Employer

The employer is responsible for ensuring that persons have the required knowledge and skills to safely deliver the activity they are employed to provide under this PGD. As a minimum, competence requirements stipulated in the PGD must be adhered to.

### 4.3. Continuing education and training

All practitioners operating under the PGD are responsible for ensuring they remain up to date with the use of vaccines included. If any training needs are identified these should be discussed with the individuals in the organisation responsible for authorising individuals to act under this PGD.

- Have undertaken NoS PGD module training on [TURAS Learn](#)
- Have attended basic life support training either face to face or online and updated in-line with individual Board requirements
- Have undertaken immunisation training where available
- Have undertaken NHS e-anaphylaxis training or equivalent which covers all aspects of the identification and management of anaphylaxis updated in-line with individual Board requirements

Maintain their skills, knowledge and their own professional level of competence in this area according to their individual Code of Professional Conduct.

## 5. Audit trail

### Record the following information:

- valid informed consent was given
- name of individual, address, date of birth and GP with whom the individual is registered if possible
- name of person that undertook assessment of individual's clinical suitability and subsequently administered the vaccine
- name and brand of vaccine
- date of administration
- dose, form and route of administration of vaccine
- batch number
- where possible expiry date
- anatomical site of vaccination

- advice given, including advice given if excluded or declines immunisation
- details of any adverse drug reactions and actions taken
- administered under PGD

Records should be kept in line with local procedures

Local policy should be followed to encourage information sharing with the individual’s General Practice

All records should be clear, legible and contemporaneous and in an easily retrievable format.

## 6. Additional references

Practitioners operating the PGD must be familiar with:

- [Immunisation against Infectious Disease \[Green Book\]](#)
- [Immunisation against infectious disease - Chapter 18 - Hepatitis B](#)
- [Vaccination of individuals with uncertain or incomplete immunisation status](#)
- current edition of British National Formulary.
- [Marketing authorisation holders Summary of Product Characteristics.](#)
- [Professional Guidance on the Administration of Medicines in Healthcare settings 2019.](#)
- [Professional Guidance on the Safe and Secure Handling of Medicines.](#)

## 7. PHS Version history

Version	Date	Summary of changes
1.0	1 June 2022	<ul style="list-style-type: none"> <li>• New PGD</li> </ul>
2.0	1 February 2024	<ul style="list-style-type: none"> <li>• This PGD has undergone minor rewording, layout, formatting changes for clarity and consistency with other PHS national specimen PGDs.</li> <li>• Inclusion criteria section updated to reflect Green Book Chapter, removing those who work with raw sewage and primates.</li> <li>• Dosage, Is the use out with the SmPC and additional information sections updated to remove reference to use of adult strength formulations for paediatric patients as there is no current shortage of paediatric formulations.</li> <li>• Dosage section updated to add advice on testing for immunity post-immunisation.</li> <li>• Additional information sections updated to include sexual health advice.</li> </ul>



		<ul style="list-style-type: none"> <li>• Observation following vaccination section updated to include advice on driving post-immunisation.</li> </ul>
2.1	22 July 2024	<ul style="list-style-type: none"> <li>• The following changes to version 2.0 of the PGD have been made:</li> <li>• Section 1.2 inclusions updated with new inclusion for those with uncertain or incomplete immunisation status and displaced persons (e.g. asylum seekers, trafficked people and refugees) who are living in multiple occupancy rooms or share bathroom facilities such as a hostel, hotel or looked after children's unit.</li> <li>• Exclusion criteria to reflect Green Book wording on previous infection.</li> <li>• Section 2.1 name of product updated with additional brands.</li> <li>• Dosage and Frequency sections updated to reference relevant tables in Chapter 18</li> <li>• Section 2.8 updated with additional brands.</li> <li>• Section 2.10 updated with additional brands.</li> <li>• Section 3.1 updated to align with Green Book chapter wording</li> </ul>

**Version history NoS**

Version	Date of change	Summary of Changes	Section heading
2.0 (Unpublished)	22 February 2024	Reference to NoS Appendix 1 and 2	Authorisation
		Training requirements for NoS	Continuing education and training
	13 March 2024	Paediatric <sup>®</sup> added to 0-15 years vaccine	Name of medicine/form/strength/Dosage
2.1.1	November 2024	Administrative error – Superseded version number incorrect. See above.	Revision History for NoS



**Appendix 1 - Healthcare Professional Agreement to Administer  
Medicine(s) Under Patient Group Direction**

I: \_\_\_\_\_ (Insert name)

Working within: \_\_\_\_\_ e.g. Area, Practice

Agree to administer the medicine(s) contained within the following Patient Group Direction:

**Patient Group Direction for the Administration of Hepatitis B Vaccine  
for Non-Travel Indications by Approved Healthcare Professionals  
Working Within NHS Grampian, Highland, Orkney, Shetland, Tayside  
and Western Isles, Version 2.1.1**

I have completed the appropriate training to my professional standards enabling me to administer the medicine(s) under the above direction. I agree not to act beyond my professional competence, nor out with the recommendations of the direction.

Signed: \_\_\_\_\_

Print Name: \_\_\_\_\_

Date: \_\_\_\_\_

Profession: \_\_\_\_\_

Professional Registration  
number/PIN: \_\_\_\_\_



**Appendix 2 - Healthcare Professionals Authorisation to Administer Medicine(s) Under Patient Group Direction**

**The Lead manager/Professional** of each clinical area is responsible for maintaining records of all clinical areas where this PGD is in use, and to whom it has been disseminated.

**The Senior Nurse/Professional** who approves a healthcare professional to administer the medicine(s) under this PGD is responsible for ensuring that they are competent, qualified and trained to do so, and for maintaining an up-to-date record of such approved persons.

**The Healthcare Professional** that is approved to administer the medicine(s) under this PGD is responsible for ensuring that they understand and are qualified, trained and competent to undertake the duties required. The approved person is also responsible for ensuring that administration is carried out within the terms of the direction, and according to their individual code of professional practice and conduct.

**Patient Group Direction for the Administration of Hepatitis B Vaccine for Non-Travel Indications by Approved Healthcare Professionals Working Within NHS Grampian, Highland, Orkney, Shetland, Tayside and Western Isles, Version 2.1.1**

**Local clinical area(s) where the listed healthcare professionals will operate under this PGD:**

<b>Name of Healthcare Professional</b>	<b>Signature</b>	<b>Date</b>	<b>Name of Manager</b>	<b>Signature</b>	<b>Date</b>

### Patient Group Direction for the Administration of Hepatitis B Vaccine for Non-Travel Indications by Approved Healthcare Professionals Working Within NHS Grampian, Highland, Orkney, Shetland, Tayside and Western Isles, Version 2.1.1

Name of Healthcare Professional	Signature	Date	Name of Manager	Signature	Date